UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2012

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California	**001-14758**	**33-0476164**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

1300 Kellogg Drive, Suite D, Anaheim, California	**92807**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code: (714) 786-4200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Commencing on September 10, 2012, Questcor Pharmaceuticals, Inc. will utilize an updated presentation for investor relations purposes.

In accordance with General Instruction B.2. of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Questcor Pharmaceuticals, Inc. Investor Presentation.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 10, 2012

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Michael H. Mulroy
Michael H. Mulroy
Senior Vice President, Chief Financial Officer, and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Questcor Pharmaceuticals, Inc. Investor Presentation.

NASDAQ: QCOR

September 2012

QUESTCOR®

Safe Harbor Statement

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: Our reliance on Acthar for substantially all of our net sales and profits; Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations; The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions; The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products; Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar; Research and development risks, including risks associated with Questcor's work in the area of NS and potential work in the area of Rheumatology, and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results; Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices; Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits; Our ability to receive high reimbursement levels from third party payers; An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities; Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results; Our ability to implement the necessary steps to implement a change in our Medicaid rebate amount for Acthar; Our ability to effectively manage our growth, including the expansion of our NS selling effort, and our reliance on key personnel; The impact to our business caused by economic conditions; Our ability to protect our proprietary rights; The risk of product liability lawsuits; Unforeseen business interruptions and security breaches; Volatility in Questcor's monthly and quarterly Acthar shipments, estimated channel inventory and end-user demand, as well as volatility in our stock price; and Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor

A biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders

QUESTCOR®

Questcor Overview

Flagship Product: H.P. Acthar GEL (repository corticotropin injection) 80 U/mL

- 19 approved indications

Key Markets*:

- Nephrotic Syndrome, Multiple Sclerosis, Infantile Spasms, Dermatomyositis/Polymyositis
- Several billion dollar market opportunity

Strategy:

- Grow Acthar sales in each key market
- Develop Rheumatology and other on-label markets

Financials:

- Profitable, cash flow positive, $133M** in cash, debt-free

QUESTCOR®

*In this presentation, the terms "Nephrotic Syndrome," "Multiple Sclerosis," "Dermatomyositis," "Polymyositis," and "Infantile Spasms," and their abbreviations, refer to the on-label indications for Acthar associated with such conditions. Investors should refer to the FDA approved Acthar label, which can be found at http://www.acthar.com/files/Acthar-PI.pdf. **As of 9/6/12

Growth in Shipped Vials Quarterly



QUESTCOR®

Q2-2012 Financial Results

Record Net Sales (up 145%) and Solid Earnings (EPS up 210%)

	Q2 –2012	Q2 –2011
Net Sales ($M)	**$112.5**	$46.0
Gross Margin	**94%**	94%
Operating Income ($M)	**$61.0**	$20.4
Fully Diluted, GAAP EPS	**$0.65**	$0.21

- Second quarter vials shipped: 4,710
- Second quarter cash flow from operations: $43.2M
- Channel inventory estimated to be within the normal range
- Medicaid reserves continue to appear adequate
- 3.7M shares repurchased during Q2-2012

July and August 2012 Metrics

- **Paid Rxs July and August 2012 (estimated)**

DX	July 2012	August 2012
Nephrotic Syndrome (NS)	108	117-122
Multiple Sclerosis (MS)	376	505-515
Infantile Spasms (IS)	39	35-40
Dermatomyositis/polymyositis (DM/PM)	1	13-15

  - **5 RA/Lupus Paid Rxs in July - August**
  - **Script counts exclude fully rebated due to 100% Medicaid rebate (Medicaid rebate likely to decrease in 2013)**
- **Shipped 2,190 vials in August 2012**
  - **Compares to 4,710 vials in Q2-12**
  - **Channel inventory level remained within the normal level on 8/31/2012**
- **1.5 Million shares repurchased at $39.15 average price**

Notes: Paid Rx information based on internal estimates. The table includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the tables are for related conditions.

QUESTCOR®

Growth in Shipped Vials - Monthly

QUESTCOR®

Questcor Strategy – Pursue Acthar Markets

- Nephrotic Syndrome (NS)
- Multiple Sclerosis (MS)
- Infantile Spasms (IS)
- Rheumatology

Acthar and Nephrotic Syndrome (NS)

- Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria)
- Can result in end-stage renal disease (ESRD), dialysis, transplant
- Acthar is approved "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus"
- Significant unmet need
  - Few treatment options
  - Goal of therapy is the significant reduction of proteinuria

QUESTCOR®

NS Scripts-Strong Continued Growth



Yellow numbers in the bars show the number of NS sales representatives making calls for the majority of the quarter. Q3 '11 and Q2 '12 included expansion and training of new sales people.

Paid Rxs

QUESTCOR®

Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.

Monthly NS Scripts History



Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indications associated with NS, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the chart are for related conditions.

QUESTCOR®

Acthar and Multiple Sclerosis (MS)

Neurodegenerative disorder

Acute treatment for relapses

Patient reported response to IV Steroids*

*Nickerson, *et al* (2011)

QUESTCOR®

ACTHAR is approved for MS exacerbations, without reference to first line or second line use but is generally positioned as second line as a matter of marketing strategy. See http://www.acthar.com/files/Acthar-PI.pdf for specific label information.

MS Scripts-Record of Consistent Grow

Paid Rxs



Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the chart are for related conditions. Yellow numbers in the bars show the number of MS sales representatives making calls for the majority of the quarter.

QUESTCOR®

Monthly MS Scripts History



Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart. About 5% of the prescriptions in the chart are for related conditions.

QUESTCOR®

Acthar and Infantile Spasms (IS)

- Devastating, refractory form of childhood epilepsy
- Unsuccessful treatment may leave infant with permanent developmental disabilities
- Ultra-rare orphan disorder
- Acthar currently used to treat 40-50% of IS patients
- Targeting select institutions



QUESTCOR®

Rheumatology

- 4 key indications on the Acthar label*
  - Dermatomyositis/Polymyositis (DM/PM)
  - Systemic lupus erythematosus (Lupus)
  - Psoriatic arthritis
  - Rheumatoid arthritis
- High unmet need; difficult to treat
- Serious health risk if unsuccessfully treated
- Significant patient population (multi $B opportunity)

QUESTCOR®

*See http://www.acthar.com/files/Acthar-PI.pdf for specific label information.

Rheumatology: Estimated Patient Populations

Indication	Total Estimated US Population	Estimated Target Acthar Population
Dermatomyositis/Polymyositis	**66K**	**~26K**
Systemic Lupus Erythematosus	250K	~50K-100K
Rheumatoid Arthritis	1.3M	~50K
Psoriatic Arthritis	500K	~40K
Juvenile Rheumatoid Arthritis	300K	-

QUESTCOR®

*Questcor estimates

How Does Acthar Work?

- Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.)
- Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors
- The primary melanocortin peptide (ACTH) in Acthar binds to all 5 melanocortin receptors (MCR1-5); other active peptides are in Acthar as well
  - Indirect effect: Acthar triggers the production of cortisol and other adrenal compounds through binding to MCR2 receptors
  - Direct effect: Acthar acts directly at the cellular level by binding to melanocortin receptors on immune cells and cells in the targeted tissues (e.g., kidney podocytes)
- All the active ingredients of Acthar have yet to be fully characterized and the mechanism of action and pharmacokinetic profile of Acthar are not fully known

QUESTCOR®

Biosimilar Pathway Difficult/Impossibl

- Difficult/impossible to reverse engineer Acthar
  - Not well characterized
- Complex pharmacology
  - Not well characterized
- Clinical trial(s) likely required
- Branded competition in specific indication possible at some point in the future

Questcor Acthar R&D Efforts: > 30 Preclinical and Clinical Studies

Understanding Acthar: science of how it works and clinical u

- **Understanding the biological properties of Acthar**
  - Specific biochemical pathways, cells, and tissues
  - Immunomodulation and anti-inflammatory
- **On-label indications**
  - Proteinuria in NS, MS flares, Lupus
- **New indications**
  - Nephrology (eg, diabetic nephropathy)
  - Indications with autoimmune/inflammatory component (eg, neurology, cardiovascular, hematology, pulmonary)

Academic Clinical Interest in Acthar: ~ 30 Investigator Initiated Studies

Understanding Acthar: clinical

- **Clinical use of Acthar**
  - Nonclinical research
  - Clinical research
- **On-label indications**
  - Proteinuria in nephrotic syndrome (NS), multiple sclerosis (MS) flares, infantile spasms, lupus
- **Off-label indications**
  - Diabetic nephropathy, traumatic brain injury, autism, MS maintenance treatment

Strategic Plan-
Focus on the Embedded Pipeline in Ac

- **Grow Nephrotic Syndrome business (107 reps)**
- **Grow Multiple Sclerosis business (58 reps)**
- **Continue to Support Infantile Spasm indication**
- **Build Rheumatology therapeutic usage (12 reps)**
- **Develop other markets for Acthar**
  - **Many on-label and new indications provide future growth opportunities**
  - **Further define and develop the unique characteristics of Acthar**

Share Repurchases: 21.4 Million Share

- 2.2 Million Preferred share buyback
- 19.2 Common share buyback
- $322 million returned to shareholders in stock buybacks
  - Average repurchase price per share: $15.02
- 58.4million shares currently outstanding
- 5.0 million shares added to buyback authorization
- 3.2 million shares remain on buyback authorization

Note: all information as of 9/6/12

2012 Repurchase Activity

- **6.0M shares repurchased during 2012, driven by:**
  - Sales/EPS increase
  - NS market traction
  - Sales force expansion
  - Rheumatology opportunity

Repurchased shares significantly improve
Q2-2012 EPS accretion from share repurchase from 2008 through 6/30/201

Investment Highlights

- Acthar has sustainable competitive advantages
- Acthar is approved for 19 indications-many in large markets with sizable unmet need
- Sales in NS and MS are growing rapidly, yet market penetration is low
- Developing new vertical market - Rheumatology
- High margins provide good operating leverage
- Profitable, cash flow positive, no debt

QUESTCOR®

NASDAQ:QCOR

September 2012

QUESTCOR®

Acthar History



MR = modified release product (eg, Acthar Gel)
DC = Discontinued

QUESTCOR®

ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary

Pro-opiomelancortin Precursor Polypeptide



SP - Signal peptide
NPP - N-terminal peptide of proopiomelanocortin
JP - Joining peptide
ACTH - Adrenocorticotropic hormone
LPH - Lipotropin hormone
MSH - Melanocyte stimulating hormone
CLIP - Corticotropin-like intermediate peptide

QUESTCOR®

Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

MCR	Prevalent Tissue/Cells with Receptor
MC1R	Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocytes Immune/Inflammatory Cells Kerantinocytes CNS
MC2R	Adrenal Cortex (Steroidogenesis), Adipocytes

Adapted from Gong 2011, Catania 2004, Schioth 1997

Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

MCR	Prevalent Tissue/Cells with Receptor
MC3R	CNS Macrophages
MC4R	Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS
MC5R	CNS Exocrine Glands Lymphocytes Podocytes

Adapted from Gong 2011, Catania 2004, Schioth 1997

MOA of Acthar in N

Acthar, Melanocortin Peptides



QUESTCOR®

Adapted From Gong 2011